{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:21:30Z","timestamp":1777044090203,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijcha.2024.101415","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T09:58:28Z","timestamp":1714903108000},"page":"101415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials"],"prefix":"10.1016","volume":"52","author":[{"given":"Aravind","family":"Dilli Babu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahib","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjani","family":"Thota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanchit","family":"Duhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiranjeevi","family":"Sainatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haroon","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lekshminarayan","family":"Raghavakurup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2024.101415_b0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008731","article-title":"Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003\u20132014","volume":"7","author":"Kirkland","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcha.2024.101415_b0010","unstructured":"Centers for Disease Control and Prevention, Facts about Hypertension, CDC. (2021). https:\/\/www.cdc.gov\/bloodpressure\/facts.htm."},{"key":"10.1016\/j.ijcha.2024.101415_b0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamainternmed.2021.6819","article-title":"Prevalence of Medications That May Raise Blood Pressure Among Adults With Hypertension in the United States","volume":"182","author":"Vitarello","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ijcha.2024.101415_b0020","article-title":"PharmD, FCSHP, axitinib: newly approved for renal cell carcinoma","volume":"3","author":"Tyler","year":"2012","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.ijcha.2024.101415_b0025","doi-asserted-by":"crossref","unstructured":"J.H. Schiller, T.V. Larson, S-H.I. Ou, S.A. Limentani, A.B. Sandler, E.E. Vokes, S. Kim, K.F. Liau, P. Bycott, A.J. Olszanski, Joachim von Pawel, Efficacy and Safety of axitinib in patients with advanced non\u2013small-cell lung cancer: results from a phase II study, J. Clin. Oncol. 27 (2009) 3836\u20133841. doi: 10.1200\/jco.2008.20.8355.","DOI":"10.1200\/JCO.2008.20.8355"},{"key":"10.1016\/j.ijcha.2024.101415_b0030","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-11-0534","article-title":"Multicenter, Phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, patients with metastatic melanoma","volume":"17","author":"Fruehauf","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijcha.2024.101415_b0035","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcha.2024.101415_b0040","doi-asserted-by":"crossref","unstructured":"Aravind Dilli Babu, S. Singh, A. Thota, Chiranjeevi Sainatham, S. Ishaq, S. Goel, Sai Gautham Kanagala, Pooled incidence of hypertension and other adverse events with axinitib in cancer patients, J. Am. College Cardiol. 83 (2024) 2501\u20132501. doi: 10.1016\/s0735-1097(24)04491-7.","DOI":"10.1016\/S0735-1097(24)04491-7"},{"key":"10.1016\/j.ijcha.2024.101415_b0045","doi-asserted-by":"crossref","unstructured":"Aravind Dilli Babu, S. Singh, Chiranjeevi Sainatham, S. Goel, Syed Muhammad Ishaq, S. Duhan, Axitinib-associated hypertensive emergency presenting as flash pulmonary edema, Chest. 164 (2023) A6268\u2013A6268. doi: 10.1016\/j.chest.2023.07.4032.","DOI":"10.1016\/j.chest.2023.07.4032"},{"key":"10.1016\/j.ijcha.2024.101415_b0050","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","article-title":"Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer","volume":"29","author":"Rugo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcha.2024.101415_b0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clgc.2016.04.005","article-title":"Overall Survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma","volume":"14","author":"Rini","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ijcha.2024.101415_b0060","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"Kindler","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijcha.2024.101415_b0065","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1093\/annonc\/mdv388","article-title":"Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma","volume":"26","author":"Kang","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcha.2024.101415_b0070","doi-asserted-by":"crossref","unstructured":"Tatsuya Ioka, Takuji Okusaka, Shinichi Ohkawa, Narikazu Boku, Akira Sawaki, Y. Fujii, Y. Kamei, S. Takahashi, Katsushi Namazu, Y. Umeyama, P. Bycott, Junji Furuse, Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial, Japanese J. Clin. Oncol. 45 (2015) 439\u2013448. doi: 10.1093\/jjco\/hyv011.","DOI":"10.1093\/jjco\/hyv011"},{"key":"10.1016\/j.ijcha.2024.101415_b0075","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.clcc.2018.02.004","article-title":"A randomized phase II study of axitinib as maintenance therapy after first-line treatment for metastatic colorectal cancer","volume":"17","author":"Gr\u00e1valos","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ijcha.2024.101415_b0080","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ijcha.2024.101415_b0085","doi-asserted-by":"crossref","unstructured":"W.A. Buikhuisen, M. Scharpfenecker, A.W. Griffioen, C.M. Korse, Harm van Tinteren, P. Baas, A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes, J. Thoracic Oncol. 11 (2016) 758\u2013768. doi: 10.1016\/j.jtho.2016.01.014.","DOI":"10.1016\/j.jtho.2016.01.014"},{"key":"10.1016\/j.ijcha.2024.101415_b0090","unstructured":"Review Manager. Vol. 5 (RevMan 5) [Computer program]. Version 5.4. Copenhagen, Denmark: The Cochrane Collaboration; 2020."},{"key":"10.1016\/j.ijcha.2024.101415_b0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11906-007-0058-7","article-title":"Chemotherapy agents and hypertension: A focus on angiogenesis blockade","volume":"9","author":"Jain","year":"2007","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ijcha.2024.101415_b0100","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/HJH.0000000000002006","article-title":"Arterial hypertension in patients under antineoplastic therapy","volume":"37","author":"Katsi","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcha.2024.101415_b0105","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin. Can. Res."},{"key":"10.1016\/j.ijcha.2024.101415_b0110","doi-asserted-by":"crossref","unstructured":"H. Kadowaki, J. Ishida, H. Akazawa, H. Yagi, A. Saga-Kamo, Masahiko Umei, R. Matsuoka, Q. Liu, H. Matsunaga, H. Maki, Y. Sato, H. Kume, Issei Komuro, Axitinib induces and aggravates hypertension regardless of prior treatment with tyrosine kinase inhibitors, Circulation Reports. 3 (2021) 234\u2013240. doi: 10.1253\/circrep.cr-21-0008.","DOI":"10.1253\/circrep.CR-21-0008"},{"key":"10.1016\/j.ijcha.2024.101415_b0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcha.2024.101415_b0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ijcha.2024.101415_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ajh\/hpt201","article-title":"Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors","volume":"27","author":"Kruzliak","year":"2013","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcha.2024.101415_b0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CMAR.S74202","article-title":"Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma","volume":"7","author":"Gunnarsson","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ijcha.2024.101415_b0135","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijcha.2024.101415_b0140","article-title":"Axitinib after sunitinib in metastatic renal cancer: preliminary results from italian \u201cReal-World\u201d SAX Study","volume":"7","author":"D\u2019Aniello","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcha.2024.101415_b0145","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.18632\/oncotarget.24599","article-title":"Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review","volume":"10","author":"Bai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijcha.2024.101415_b0150","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.ijcha.2024.101415_b0155","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41371-020-0391-8","article-title":"Hypertension management in cardio-oncology","volume":"34","author":"Essa","year":"2020","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcha.2024.101415_b0160","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of Antiangiogenic Therapy-Induced Hypertension","volume":"60","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcha.2024.101415_b0165","doi-asserted-by":"crossref","unstructured":"van Dorst, Sumeyye Kabadayi, Esther Oomen-de Hoop, J. Danser, R.H.J. Mathijssen, Jorie Versmissen, Treatment and Implications of vascular endothelial growth factor inhibitor\u2010induced blood pressure rise: a clinical Cohort Study, J. Am. Heart Assoc. 12 (2023). doi: 10.1161\/jaha.122.028050.","DOI":"10.1161\/JAHA.122.028050"},{"key":"10.1016\/j.ijcha.2024.101415_b0170","unstructured":"Consorzio Oncotech, Pfizer, Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous Complete Response (AxIn Study)., Clinicaltrials.gov. (2023). https:\/\/clinicaltrials.gov\/study\/NCT05817903. (accessed April 22, 2024)."},{"key":"10.1016\/j.ijcha.2024.101415_b0175","unstructured":"A. Apolo, National Cancer Institute (NCI), Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma\/Paraganglioma, Clinicaltrials.gov. (2020). https:\/\/clinicaltrials.gov\/study\/NCT01967576 (accessed April 22, 2024)."},{"key":"10.1016\/j.ijcha.2024.101415_b0180","unstructured":"Peking Union Medical College Hospital, Shanghai Junshi Bioscience Co., Ltd., Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors: a Single-arm, Non-randomized, Single-center Phase II Trial, Clinicaltrials.gov. (2023). https:\/\/clinicaltrials.gov\/study\/NCT04010071 (accessed April 22, 2024)."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T11:24:19Z","timestamp":1716636259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":36,"alternative-id":["S2352906724000812"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101415","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101415"}}